Conduit Pharmaceuticals Inc (CDT)

Mar 31, 2025, 8:30 AM EDT - 4 days ago

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Mar 19, 2025, 8:30 AM EDT - 16 days ago

Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904

Mar 6, 2025, 9:35 AM EST - 4 weeks ago

Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel

Feb 20, 2025, 8:00 AM EST - 6 weeks ago

Conduit Progresses Phase II of its AI Initiative with Sarborg

Feb 13, 2025, 8:00 AM EST - 7 weeks ago

Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model

Feb 11, 2025, 9:00 AM EST - 7 weeks ago

Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note

Feb 7, 2025, 8:00 AM EST - 2 months ago

Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development

Jan 28, 2025, 5:30 AM EST - 2 months ago

Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence

Jan 23, 2025, 8:00 AM EST - 2 months ago

Conduit Pharmaceuticals Inc. Announces Reverse Stock Split

Dec 12, 2024, 7:30 AM EST - 4 months ago

Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics

Nov 21, 2024, 7:30 AM EST - 4 months ago

Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders

Nov 19, 2024, 4:30 PM EST - 4 months ago

Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Nov 4, 2024, 7:30 AM EST - 5 months ago

Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline

Nov 1, 2024, 4:45 PM EDT - 5 months ago

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

Aug 12, 2024, 7:00 AM EDT - 8 months ago

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Aug 8, 2024, 6:30 AM EDT - 8 months ago

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

May 22, 2024, 7:00 AM EDT - 11 months ago

AstraZeneca furthers ambition to transform outcomes in early lung cancer and ​redefine metastatic breast cancer treatment at ASCO 2024​

AZN

May 21, 2024, 8:00 AM EDT - 11 months ago

Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO

Mar 19, 2024, 7:00 AM EDT - 1 year ago

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe's Leading Life Sciences Hub

Jan 31, 2024, 8:30 AM EST - 1 year ago

Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Nov 2, 2023, 8:30 AM EDT - 1 year ago

Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference

Oct 11, 2023, 8:30 AM EDT - 1 year ago

Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656

Oct 11, 2023, 8:30 AM EDT - 1 year ago

ClinConnect Partners with Conduit Pharmaceuticals on Cocrystal Development Program for AZD1656

Sep 22, 2023, 9:01 AM EDT - 1 year ago

Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination